Prescriptions for weight-loss drugs surged in 2024 and were much more popular in some states, particularly those in the South ...
Meds like Wegovy are all over the news. But are they right for you, especially if you’re older than the average user?
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
People are reporting that their weight-loss medication helps them steer clear of drugs and alcohol. Studies are promising, ...
The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...
It's what most investors want more than anything else from their stocks. Three Motley Fool contributors think they've identified no-brainer growth stocks in the healthcare sector to buy in December.
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
The European Commission granted unconditional approval to Novo Holdings’ $16.5 billion takeover of Catalent, a decision both ...
The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...